Enterprise Profile

Revenue in millions of dollars

BD Diagnostics is a leading provider of products for the safe collection and transport of diagnostic specimens and of instrumentation for quick, accurate analysis across a broad range of infectious diseases, including the growing problem of healthcare-associated infections (HAIs). The segment is composed of two operating units: Preanalytical Systems, a world leader in sample collection, and Diagnostic Systems, a leader in microbiology testing products, and molecular assays.

Principal products and services include integrated systems for specimen collection; an extensive line of safety-engineered blood collection products and systems; plated media; automated blood culturing systems; molecular testing systems for sexually transmitted diseases and healthcare-associated infections; microorganism identification and drug susceptibility systems; and rapid manual testing products.
     BD Diagnostics focuses on improving health outcomes for patients and economic outcomes for laboratories by providing solutions that elevate quality, reduce costs, guide medical decisions and improve the productivity of laboratory systems. Developing products that effectively integrate laboratory work processes, diagnostic testing procedures and information management is central to the business. In each of its businesses, BD Diagnostics seeks both to grow its core product platforms and innovate to expand its range of product and service solutions.
     Preanalytical Systems is continuing its focus on specimen collection and accelerating growth through continued emphasis on safety through safety-engineered sharps and plastic evacuated tubes. Innovation, an integral part of this effort, has led to second- and third-generation safety-engineered products offering greater protection and improved functionality. The conversion of emerging markets to evacuated tubes is also a priority.
     Looking ahead, Preanalytical Systems is concentrating on new opportunities driven by emerging technologies–including molecular diagnostics and proteomics–and will look to build capabilities in the areas of sample collection, stabilization and processing.
     Diagnostic Systems continues to be a leader in microbiology and infectious disease diagnostics. Its focus on growth media–for both the clinical and industrial market segments–is the foundation of strong customer relationships and an entry point for instrument platforms. For example, BD BACTEC systems are a critical tool for microbiologists seeking clinically relevant answers for patients with life-threatening infections. The 2006 acquisition of GeneOhm Sciences provides BD with additional molecular testing capability for the detection of bacterial organisms, especially those causing HAIs. This newly acquired capability, coupled with the BD ProbeTec/BD Viper system, gives BD a growing position in molecular diagnostics.
     Looking forward, Diagnostic Systems will leverage its unique instrument product portfolio and engineering capabilities to provide a range of systems to rapidly diagnose infectious disease.

The BD Viper platform combines state-of-the-art molecular testing and robotic automation to help clinical laboratories detect Chlamydia trachomatis and Neisseria gonorrhoeae in patient samples earlier and more accurately, which can lead to more timely and effective treatment. The BD GeneOhm MRSA assay is a qualitative in vitro diagnostic test for the direct detection of nasal colonization by methicillin-resistant Staphylococcus aureus (MRSA) to aid in the prevention and control of healthcare-associated infections. The BD Free Flow Electrophoresis System is the only separation system that provides high-resolution fractionation and purification across an amazingly broad range-from peptides and proteins to cellular organelles. The BD Vacutainer Push Button Blood Collection Set is BD’s next-generation safety-engineered wingset offering the healthcare worker in-vein activation and split-second protection at the push of a button.